Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004718 · ClinicalTrials.gov registry record · NA
Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT01004718 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants.
The verdict
NCT01004718, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.
Interventions
- PROCEDURE Computed Tomography
- RADIATION Fludeoxyglucose F18
- PROCEDURE Positron emission tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-11-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01004718
The ClinicalTrials.gov registry entry for NCT01004718 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Computed Tomography is the first listed.
NCT01004718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01004718 about?
NCT01004718 is a clinical study titled "Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)". RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determ...
What is the current status of trial NCT01004718?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2009-05. Estimated completion is 2014-11-05.
What interventions are being tested in trial NCT01004718?
The interventions under investigation include: Computed Tomography (PROCEDURE), Fludeoxyglucose F18 (RADIATION), Positron emission tomography (PROCEDURE).
Who is sponsoring clinical trial NCT01004718?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.